TURNING POINT THERAPEUTICS I (TPTX) Stock Price & Overview
NASDAQ:TPTX • US90041T1088
Current stock price
The current stock price of TPTX is 76.01 USD. Today TPTX is up by 0.69%. In the past month the price increased by 1.73%. In the past year, price increased by 18.56%.
TPTX Key Statistics
- Market Cap
- 3.775B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -4.79
- Dividend Yield
- N/A
TPTX Stock Performance
TPTX Stock Chart
TPTX Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to TPTX. When comparing the yearly performance of all stocks, TPTX is one of the better performing stocks in the market, outperforming 98.65% of all stocks.
TPTX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to TPTX. While TPTX has a great health rating, there are worries on its profitability.
TPTX Earnings
TPTX Forecast & Estimates
15 analysts have analysed TPTX and the average price target is 74.9 USD. This implies a price decrease of -1.46% is expected in the next year compared to the current price of 76.01.
For the next year, analysts expect an EPS growth of -43.06% and a revenue growth -78.46% for TPTX
TPTX Groups
Sector & Classification
TPTX Financial Highlights
Over the last trailing twelve months TPTX reported a non-GAAP Earnings per Share(EPS) of -4.79. The EPS decreased by -56.03% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -33959.03% | ||
| ROA | -40.59% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
TPTX Ownership
TPTX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.83 | 362.828B | ||
| AMGN | AMGEN INC | 15.27 | 187.828B | ||
| GILD | GILEAD SCIENCES INC | 15.62 | 171.453B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.14 | 113.963B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.86 | 78.412B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 41.29 | 40.854B | ||
| INSM | INSMED INC | N/A | 29.992B | ||
| NTRA | NATERA INC | N/A | 27.569B | ||
| BIIB | BIOGEN INC | 11.44 | 26.995B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.81 | 23.31B | ||
| MRNA | MODERNA INC | N/A | 20.276B | ||
| EXAS | EXACT SCIENCES CORP | 345.14 | 20.026B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 18.929B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About TPTX
Company Profile
Turning Point Therapeutics, Inc. is a clinical-stage oncology biopharmaceutical company, which engages in designing and developing next-generation therapies that target genetic drivers of cancer to improve the lives of patients. The company is headquartered in San Diego, California and currently employs 248 full-time employees. The company went IPO on 2019-04-17. The firm is engaged in designing and developing therapies that target genetic drivers of cancer to improve the lives of patients. The company develops a macrocycle platform from which it designs its pipeline of small, compact tyrosine kinase inhibitors (TKIs). The TKIs generated from its drug discovery platform address unmet needs in TKI naive and resistance settings. The Company’s drug candidate, repotrectinib (TPX-0005), is in Phase I/II trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with NTRK+ or ALK+ advanced solid tumors. Its multi-cohort Phase II registrational portion of TRIDENT-1 is ongoing at sites in North America, Europe and the Asia-Pacific regions. The Company’s pipeline includes multi-targeted kinase inhibitors: TPX-0046 (a novel RET inhibitor), Elzovantinib (TPX-0022) (a novel MET/CSF1R/SRC inhibitor) and TPX-0131.
Company Info
IPO: 2019-04-17
TURNING POINT THERAPEUTICS I
10628 Science Center Drive, Suite 200
San Diego CALIFORNIA 92121 US
CEO: Athena Countouriotis
Employees: 248
Phone: 18589265251.0
TURNING POINT THERAPEUTICS I / TPTX FAQ
What does TPTX do?
Turning Point Therapeutics, Inc. is a clinical-stage oncology biopharmaceutical company, which engages in designing and developing next-generation therapies that target genetic drivers of cancer to improve the lives of patients. The company is headquartered in San Diego, California and currently employs 248 full-time employees. The company went IPO on 2019-04-17. The firm is engaged in designing and developing therapies that target genetic drivers of cancer to improve the lives of patients. The company develops a macrocycle platform from which it designs its pipeline of small, compact tyrosine kinase inhibitors (TKIs). The TKIs generated from its drug discovery platform address unmet needs in TKI naive and resistance settings. The Company’s drug candidate, repotrectinib (TPX-0005), is in Phase I/II trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with NTRK+ or ALK+ advanced solid tumors. Its multi-cohort Phase II registrational portion of TRIDENT-1 is ongoing at sites in North America, Europe and the Asia-Pacific regions. The Company’s pipeline includes multi-targeted kinase inhibitors: TPX-0046 (a novel RET inhibitor), Elzovantinib (TPX-0022) (a novel MET/CSF1R/SRC inhibitor) and TPX-0131.
Can you provide the latest stock price for TURNING POINT THERAPEUTICS I?
The current stock price of TPTX is 76.01 USD. The price increased by 0.69% in the last trading session.
Does TPTX stock pay dividends?
TPTX does not pay a dividend.
What is the ChartMill rating of TURNING POINT THERAPEUTICS I stock?
TPTX has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Where is TURNING POINT THERAPEUTICS I (TPTX) stock traded?
TPTX stock is listed on the Nasdaq exchange.
Can you provide the PE ratio for TPTX stock?
TURNING POINT THERAPEUTICS I (TPTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.79).
Can you provide the ownership details for TPTX stock?
You can find the ownership structure of TURNING POINT THERAPEUTICS I (TPTX) on the Ownership tab.